1.
Ter Arkh
; 91(5): 26-33, 2019 May 15.
Artigo
em Russo
| MEDLINE
| ID: mdl-32598673
RESUMO
AIM: to evaluate the role of laboratory biomarkers in monitoring effectiveness of rituximab (RTM) biosimilar therapy in a total dose of 1200 mg. MATERIALS AND METHODS: 20 patients (pts) with rheumatoid arthritis (RA) (18 woman, mean age 61.5(54-66.5) years, mean disease duration 39.5(20-84) months, mean DAS28 5.6(4.9-6.8)) received two intravenous RTM biosimilar infusions (600 mg â2) in combination with DMARDs and glucocorticoids. Laboratory biomarkers were assessed at baseline and weeks 12 and 24 after the first infusion of RTX. RESULTS: RTM biosimilar induced decreases in DAS28, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) at week 12 and 24, p.
Assuntos
Antirreumáticos , Artrite Reumatoide , Medicamentos Biossimilares , Idoso , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Biomarcadores , Medicamentos Biossimilares/uso terapêutico , Sedimentação Sanguínea , Proteína C-Reativa , Feminino , Humanos , Pessoa de Meia-Idade , Rituximab/uso terapêutico , Resultado do Tratamento
2.
Pediatr Akus Ginekol
; (2): 50-2, 1974.
Artigo
em Ucraniano
| MEDLINE
| ID: mdl-4438025
3.
Pediatr Akus Ginekol
; (2): 55-8, 1972.
Artigo
em Ucraniano
| MEDLINE
| ID: mdl-4680416
4.
Pediatr Akus Ginekol
; 5: 17-9, 1970.
Artigo
em Ucraniano
| MEDLINE
| ID: mdl-5504841